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Abstract: Non Celiac Gluten sensitivity (NCGS) was originally described in the 1980s and 
recently a “re-discovered” disorder characterized by intestinal and extra-intestinal 
symptoms related to the ingestion of gluten-containing food, in subjects that are not 
affected with either celiac disease (CD) or wheat allergy (WA). Although NCGS frequency 
is still unclear, epidemiological data have been generated that can help establishing the 
magnitude of the problem. Clinical studies further defined the identity of NCGS and its 
implications in human disease. An overlap between the irritable bowel syndrome (IBS) and 
NCGS has been detected, requiring even more stringent diagnostic criteria. Several studies 
suggested a relationship between NCGS and neuropsychiatric disorders, particularly 
autism and schizophrenia. The first case reports of NCGS in children have been described. 
Nutrients 2013, 5 3841 
 
Lack of biomarkers is still a major limitation of clinical studies, making it difficult to 
differentiate NCGS from other gluten related disorders. Recent studies raised the 
possibility that, beside gluten, wheat amylase-trypsin inhibitors and low-fermentable, 
poorly-absorbed, short-chain carbohydrates can contribute to symptoms (at least those 
related to IBS) experienced by NCGS patients. In this paper we report the major advances 
and current trends on NCGS. 
Keywords: gluten sensitivity; celiac disease; wheat allergy; gluten-related disorders; 
gluten-free diet 
 
1. Introduction 
Gluten sensitivity (GS) was originally described in the 1980s [1] and a recently “re-discovered” 
syndrome entity, characterized by intestinal and extra-intestinal symptoms related to the ingestion of 
gluten-containing food, in subjects that are not affected with either celiac disease (CD) or wheat 
allergy (WA). Following the landmark work by Sapone and coworkers, describing the clinical and 
diagnostic features of GS in the year 2010 [2], a rapidly increasing number of papers have been 
published by many independent groups, confirming that GS should definitely be included in the 
spectrum of gluten-related disorders. However, many aspects of GS epidemiology, pathophysiology, 
clinical spectrum, and treatment are still unclear. Given the recent increase of the gluten-free market 
worldwide, partially sustained by individuals who claim a medical necessity to undertake a gluten-free 
diet (GFD), there is a need of “separating the wheat from the chaff” [3]. This goal will be achieved by 
(a) proper scientific information, (b) shared definitions, and (c) prospective, multi-center studies 
addressing the many unsolved issues on GS. In order to develop a consensus on new nomenclature and 
classification of gluten-related disorders, a panel of experts first met in London, in February 2011. The 
panel proposed a series of definitions and developed a diagnostic algorithm that has been recently 
published [4]. 
After the 2011 London Meeting, many new papers have been published on GS. Although its 
frequency in the general population is still unclear, epidemiological data have been generated that can 
help establish the magnitude of the problem. Clinical studies further defined the identity of GS and its 
possible implications in human disease. An overlap between the irritable bowel syndrome (IBS) and 
GS has been suspected, requiring even more stringent diagnostic criteria. The first case reports of GS 
in children have been described. Lack of biomarkers is still a major limitation of clinical studies, 
making the differential diagnosis with other gluten related disorders, as well conditions independent to 
gluten exposure, difficult. 
Evaluation and discussion of this new information was the aim of a Second Expert Meeting on GS 
that was held in Munich, November 30–December 2, 2012. In this paper we report the major advances 
and current trends on GS, as presented and debated at the Munich meeting. 
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2. Nomenclature 
At least three papers have recently addressed the issue of defining gluten-related disorders [4–6]. 
Interestingly, one of these [4] ranks among the most frequently downloaded paper of the publishing 
journal (BMC Medicine), particularly by physicians, internists or general pediatricians, and directors of 
diagnostic labs. There is a general agreement that the term “gluten-related disorders” is the umbrella-term 
to be used for describing all conditions related to ingestion of gluten-containing food. CD is a chronic 
small intestinal, immune-mediated, enteropathy precipitated by exposure to dietary gluten and related 
prolamines in genetically predisposed individuals, characterized by specific autoantibodies against 
tissue transglutaminase 2 (anti-TG2) and endomysium (EMA). WA is an adverse immunologic 
reaction to wheat proteins. In the pathogenesis of WA, wheat specific IgE antibodies play a central 
role, however non-IgE-mediated WA does exist [7], and this form may be difficult to distinguish from GS. 
GS, which this review will focus on primarily, is a condition in which symptoms are triggered by 
gluten ingestion, in the absence of celiac-specific antibodies and of classical celiac villous atrophy, 
with variable Human Leukocyte Antigen (HLA) status and variable presence of first generation  
anti-gliadin antibodies (AGA). The “labeling” of this disorder was a matter of debate among the panel 
experts. In order to avoid confusion with CD, sometimes defined as gluten-sensitive enteropathy, “non 
celiac gluten sensitivity” (NCGS) appeared as an improved definition. Doubtless this is still too vague 
a terminology, simply reflecting the poor knowledge of the pathophysiology of this condition. As 
triggering cereal proteins could include fractions other than gluten (see Section 10 below) some 
panelists were in favor of “non-celiac wheat (protein) sensitivity”, a terminology that would however 
conflict with the possibility that other gluten-containing cereals (rye, barley) may be offensive for the 
“gluten sensitive” patient. Bearing these limitations in mind, the experts’ panel agreed that this entity 
can provisionally be defined as NCGS, a definition requiring refinement in the future. 
3. Epidemiology 
The overall prevalence of NCGS in the general population is still unknown, mainly because many 
patients are currently self-diagnosed and start a GFD without medical advice or consultation. 
However, new data confirm that this is not an uncommon disorder at all. In a region of New Zealand, 
5% of children reported non-CD-related avoidance of gluten-containing food [8]. Gluten avoidance 
was associated with improvement of nonspecific behavioral and gastrointestinal complaints [9]. It 
remains to be elucidated how many children reporting gluten avoidance were indeed affected by 
NCGS, as the vast majority of the children involved in this study were not tested for CD nor 
underwent to an intestinal biopsy. In a US study performed on 7762 unselected persons aged six years 
or older who participated in the National Health and Nutrition Examination Survey (NHANES)  
2009–2010, Digiacomo et al. found a 0.55% prevalence of persons on a self-reported GFD. The 
prevalence was higher in females and older participants [10]. Many of the NHANES subjects on a 
GFD could indeed be affected by NCGS, however this is likely to be an underestimate as (a) the 
possible relationship between gastro-intestinal symptoms and gluten intake was not systematically 
explored in this population sample, and (b) the NHANES survey was conducted before NCGS was 
described in the medical literature. 
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The analysis of the epidemiology of IBS provides an indirect estimate of intestinal NCGS 
frequency. According to recent population-based surveys performed in Northern Europe, the 
prevalence of IBS in the general adult population is 16%–25% [11,12]. In a selected (and, therefore, 
probably biased) series of adults with IBS, the frequency of NCGS, documented by a double-blind, 
placebo-controlled challenge, was 28% [13]. In the large study performed by Carroccio et al., 276 out 
of 920 (30%) subjects with IBS-like symptoms, according to the Rome II criteria, suffered from wheat 
sensitivity or multiple food hypersensitivity, including wheat sensitivity [14]. Should a consistent 
proportion of IBS patients be affected with NCGS, the prevalence of NCGS in the general population 
could well be higher than CD (1%). 
Although risk factors for NCGS have not yet been identified, the disorder seems to be  
more common in females and in young/middle age adults. The prevalence of NCGS in children is  
still unknown. 
4. Clinical Picture and Natural History 
NCGS is characterized by symptoms that usually occur soon after gluten ingestion, disappear with 
gluten withdrawal and relapse following gluten challenge, within hours or few days. The “classical” 
presentation of NCGS is a combination of IBS-like symptoms, including abdominal pain, bloating, 
bowel habit abnormalities (either diarrhea or constipation), and systemic manifestations such as “foggy 
mind”, headache, fatigue, joint and muscle pain, leg or arm numbness, dermatitis (eczema or skin 
rash), depression, and anemia [2,15]. When seen at the specialty clinic, many NCGS patients already 
report the causal relationship between the ingestion of gluten-containing food and worsening of 
symptoms. In children, NCGS manifests with typical gastrointestinal symptoms, such as abdominal 
pain and chronic diarrhea, while the extra-intestinal manifestations seem to be less frequent, the most 
common extra-intestinal symptom being tiredness [16]. 
During the last decade, several studies suggested a relationship between NCGS and 
neuropsychiatric disorders (see following paragraphs). 
While it is undisputable that in some cases the positive effect of gluten withdrawal can be explained 
by a placebo effect, this is not the case in true NCGS. In a double-blind randomized placebo-controlled 
study design, Biesiekierski et al. found that IBS-like symptoms of NCGS were more frequent in the 
gluten-treated group (68%) than in subjects on placebo (40%) [13]. Furthermore a recent study found 
no significant differences between CD and NCGS patients regarding personality traits, level of 
somatization, quality of life, anxiety, and depressive symptoms. The somatization level was low in 
both diseases. Additionally, symptom increase after a gluten challenge was not related to personality in 
NCGS patients [17]. 
No major complication of untreated NCGS has so far been described; especially autoimmune 
comorbidity, as observed in CD, has not been reported so far. However, natural history data on NCGS 
are still lacking. Therefore it is difficult to draw firm conclusions on the outcome of this condition. 
5. NCGS and IBS: A Complex Relationship 
The complex relationship between IBS and dietary proteins has been recently reviewed [18]. 
Patients with CD often report symptoms compatible with IBS persisting after treatment with the GFD. 
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In a recent meta-analysis the pooled prevalence of IBS-type symptoms in patients with treated CD was 
38.0% (95% CI, 27.0%–50.0%). The pooled odds ratio (OR) for IBS-type symptoms was higher in 
patients with CD than in controls (5.60; 95% CI, 3.23–9.70). In patients who were non-adherent with a 
GFD, the pooled OR for IBS-like symptoms, compared with those who were strictly adherent, was 
2.69 (95% CI, 0.75–9.56) [19]. 
That gluten ingestion may elicit gastrointestinal symptoms in non-CD patients has recently been 
shown in subjects affected with the D variant (diarrhea-predominant) of IBS, by Vazquez-Roque and 
coworkers. Subjects on a gluten containing diet (GCD) had more bowel movements per day, 
particularly those with HLA-DQ2 and/or DQ8 genotypes. The GCD was associated with higher small 
bowel permeability. Patients on the GCD had a small decrease in expression of zonula occludens 1 in 
small bowel mucosa, and significant decreases in expression of zonula occludens 1, claudin-1, and 
occludin in rectosigmoid mucosa; again the effects of the GCD on expression were significantly 
greater in HLA-DQ2/8–positive patients. On the other hand, the GCD vs. the GFD had no  
significant effects on gastrointestinal transit or histology. It was concluded that gluten alters bowel 
barrier functions in patients with IBS-D, particularly in HLA-DQ2/8–positive patients. These data  
provided mechanistic explanations for the observation that gluten withdrawal may improve patient 
symptoms in IBS [20]. 
How specific the effect of gluten withdrawal from the diet of patients with IBS is, still remains to 
be elucidated. Besides gluten, wheat, and wheat derivatives contain other constituents that could play a 
role in triggering symptoms in IBS patients, e.g., amylase-trypsin inhibitors (ATIs, see below) and 
fructans. In a second study, Biesiekirski et al. reported on 37 patients with IBS/self-reported NCGS 
investigated by a double-blind crossover trial. Patients were randomly assigned to a period of reduced 
low-fermentable, poorly-absorbed, short-chain carbohydrates (fermentable oligo-, di-, and mono-saccharides 
and polyols = FODMAPs) diet and then placed on either a gluten or whey proteins challenge. In all 
participants, gastrointestinal complaints consistently improved during reduced FODMAP intake, but 
significantly worsened to a similar degree when their diets included gluten or whey proteins [21]. 
FODMAPS list includes fructans, galactans, fructose, and polyols that are contained in several 
foodstuffs, including wheat, vegetables, and milk derivatives. These results raise the possibility that 
the positive effect of the GFD in patients with IBS is an unspecific consequence of reducing 
FODMAPs intake, given that wheat is one of the possible sources of FODMAPs. However, it should 
be stressed that FODMAPs cannot be entirely and exclusively responsible for the symptoms 
experienced by NCGS subjects, since these patients experience a resolution of symptoms while on a 
GFD despite continuing to ingest FODMAPs from other sources, like legumes (a much richer source 
of FODMPs than wheat). Nevertheless, based on the results reported by Biesiekirski et al. is also 
possible that there are IBS cases entirely due to FODMAPs that, therefore, cannot be classified as 
affected by NCGS [21]. 
6. Is Autism Part of the NCGS Spectrum? 
Autism Spectrum Disorders (ASD) are chronic behavioral conditions, with onset before three years 
of age. ASD are one of the fastest growing developmental disabilities in the United States. They 
present with a wide range of stereotyped, repetitive behaviors, social and language impairment. 
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Function and outcome is affected not only by core deficits but also by associated behaviors such as 
hyperactivity, aggression, anxiety, and depression. Many studies have indicated that behavioral 
therapy and medication may be at least partially helpful in the management of children with ASD. 
Research on the effect of diet and nutrition on autism has been increasing in the past two decades, 
particularly on the symptoms of hyperactivity and attention. One of the most popular interventions for 
ASD is the gluten free casein free (GFCF) diet. 
The possible effect of the GFCF in children with autism is not due to underlying CD, since an 
association between these two conditions has never been clearly confirmed by serological screening 
studies [22]. It has been hypothesized that some symptoms may be caused by opioid peptides formed 
from the incomplete breakdown of foods containing gluten and casein. Increased intestinal 
permeability, also referred to as the “leaky gut syndrome,” has been suspected in ASD to be part of the 
chain of events that allows these peptides to cross the intestinal membrane, enter the bloodstream, and 
cross the blood-brain barrier, affecting the endogenous opiate system and neurotransmission within the 
nervous system. The resulting excess of opioids is thought to lead to behaviors noted in ASD, and the 
removal of these substances from the diet could determine a change in autistic behaviors [23]. The 
leaky gut/autism connection has fuelled a strong debate within the scientific community, far from 
being settled. A recent study has reported a high percentage of abnormal intestinal permeability test (as 
established by the lactulose/mannitol ratio) among patients with autism (36.7%) and their relatives 
(21.2%) compared with normal subjects (4.8%). Patients with autism on a reported GFCF diet had 
significantly lower intestinal permeability test values compared with those who were on an 
unrestricted diet and controls [24]. However, the degree of correlation between abnormal intestinal 
permeability to sugars (lactulose and mannitol) and proteins/peptides remains to be established. It 
should also be pointed out that, in a pilot study, Robertson et al. did not detect any changes in 
intestinal permeability in a small cohort of ASD children [25]. The finding of IgG class antibodies 
directed against food antigens is considered indirect evidence of increased intestinal permeability. 
Children with autism have significantly higher levels of IgG antibody (but not IgA) to gliadin 
compared with healthy controls, particularly in those with gastrointestinal symptoms [26]. Recent 
studies confirmed these findings and also reported an increase in antibodies directed to several other 
food allergens, including casein and whole milk [27]. 
Despite its popularity, the efficacy of the GFCF diet in improving autistic behavior remains not 
conclusively proven. A 2008 Cochrane review reported that only two small RCTs investigated the 
effect of GFCF diet in children with ASD (n = 35). There were only three significant treatment effects 
in favor of the diet intervention: overall autistic traits, mean difference (MD) = −5.60; social isolation, 
MD = −3.20 and overall ability to communicate and interact, MD = 1.70. In addition three outcomes 
were not different between the treatment and control group while differences for ten outcomes could 
not be analyzed because data were skewed. The review concluded that the evidence for efficacy of 
these diets is poor, and large scale, good quality randomized controlled trials are needed [28]. 
By using a two-stage, randomized, controlled study of GFCF diet of children with ASD, Whiteley 
and coworkers recently reported significant group improvements in core autistic and related behaviors 
after eight and 12 months on diet. The results showed a less dramatic change between children having 
been on diet for eight and children in diet for 24 months, possibly reflective of a plateau effect [29]. 
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The above data suggest that removing gluten from the diet may positively affect the clinical 
outcome in some children diagnosed with ASD, indicating that autism may be part of the spectrum of 
NCGS, at least in some cases. However, a word of caution is necessary to stress the fact that only a 
small, selected sub-group of children affected by ASD may benefit from an elimination diet. 
Additional investigations are required in order to identify phenotypes based on best- and non-response 
to dietary modifications and assess any biological correlates including anthropometry before 
considering a dietary intervention. 
7. Gluten-Related Disorders and Schizophrenia 
An association between schizophrenia and CD was noted in reports spanning back to the  
1960s [30]. In 1986 a double-blind gluten-free/gluten-load controlled trial of 24 patients conducted by 
Vlissides et al. showed changes in symptom profile of schizophrenics in response to exclusion of 
gluten from the diet [31]. On the other hand, a small blind study conducted by Potkin et al. showed no 
differences in the clinical status of eight schizophrenic patients on a 5-week gluten challenge in an  
in-patient setting, as measured by the Brief Psychiatric Rating Scale [32]. A subsequent study by 
Storms et al. tested 26 schizophrenic patients on a locked ward assigned to either a gluten-free or high 
gluten diet. No differences were found between the groups on their performance in a battery of 
psychological tests [33]. A recent study using blood samples from the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) found that 5.5% of the subjects with schizophrenia had a high 
level of anti-tTG antibodies (compared to 1.1% in the healthy control sample) and 23.1% had AGA 
IgG positivity compared with 3.1% in controls. Interestingly enough, a large proportion of tTG 
positive subjects resulted EMA negative, questioning the possibility that their tTG positivity was 
related to CD. Indeed, only 2% of schizophrenic patients fulfilled the CD diagnostic criteria (both  
anti-tTG and EMA positive), questioning the role of CD in schizophrenia [34]. Additional studies 
revealed that most of the tTG positive subjects were tTG-6 positive, suggesting that these antibodies 
are more a biomarker of neuro-inflammation than CD [35]. This study indicated the existence of a 
specific immune response to gluten in some of these patients, probably related to NCGS. Other studies 
confirmed the high prevalence of antibodies to AGA among people with schizophrenia [36], however 
the exact mechanism underlying the observed improvement of symptoms in some patients with the 
GFD has remained elusive. Immunological mechanisms have been proposed, including the assertion 
that a subgroup of schizophrenics suffer from food intolerances that benefit from the adoption of a 
GFD. The beneficial effect of a GFD may also be achieved via circulating food-derived peptides 
(exorphins) exerting an influence on physiological processes in the brain (same mechanism as 
described in the autism paragraph). If it were true that a subset of schizophrenic patients did exhibit 
symptoms due to sensitivity to gluten, then not only would treatment for these individuals be easier 
and more efficient than neuroleptics but also their quality of life would improve. 
In summary, the role of NCGS in conditions affecting the nervous system remains a highly debated 
and controversial topic that requires additional, well-designed studies to establish the real role of 
gluten as a triggering factor in these diseases. 
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8. Laboratory Evaluation 
So far no specific biomarker of NCGS has been identified. Recently, Volta and colleagues reported 
on the pattern of CD serology found in 78 untreated patients affected with NCGS. Many patients 
displayed an elevated prevalence of high titer, “first-generation” IgG AGA directed against native 
gliadin (56.4%). The prevalence of IgG AGA detected in NCGS, although lower than that found in CD 
(81.2%), was much higher than other pathologic conditions such as connective tissue disorders (9%) 
and autoimmune liver diseases (21.5%) as well as in the general population and healthy blood donors 
(2%–8%). On the other hand, the prevalence of IgA AGA in NCGS patients was very low (7.7%). 
Noteworthy, the “best” CD markers, namely IgG deamidated gliadin peptide (DGP) antibodies, IgA 
tTGA, and IgA EMA, were always negative in NCGS patients, except for an isolated positivity at a 
very low titer for IgG DGP. The consistent negativity for IgG DGP, whose synthesis “in vivo” is an 
expression of the interaction between tissue transglutaminase and gliadin peptides, seems to exclude 
the involvement of adaptive immunity in NCGS pathogenesis. Interestingly enough, ELISA activities 
of IgA tTGA in NCGS patients were very low with 30% of them displaying values < 1 AU (none of 
them had IgA deficiency) [15]. 
The CD-predisposing HLA-DQ2 and DQ8 genotypes are found in 50% of NCGS patients, a 
prevalence that is lower than CD (95%) and only slightly higher than the general population (30%) [4]. 
In the work of Sapone and coworkers all subjects (11 patients with NCGS, 13 with CD, and  
seven controls), underwent upper duodenal endoscopy for small intestinal biopsy. Those with NCGS 
revealed normal to mildly inflamed mucosa (Marsh 0 to 1), while all CD patients showed partial or 
subtotal villous atrophy with crypt hyperplasia. As expected, CD patients had increased numbers of 
CD3+ IELs (>50/100 enterocytes) compared to controls, while NCGS patients had a number of CD3+ 
IELs intermediate between CD patients and controls in the context of relatively conserved villus 
architecture. The numbers of TCR-γδ IELs were only elevated in CD subjects (>3.4/100 enterocytes), 
while in NCGS patients the numbers of γδ IELs were similar to those in controls [2]. Recently, 
activation of circulating basophils [14] and increased infiltration of duodenal lamina propria with 
eosinophils [37] have been described. 
9. Diagnosis 
NCGS diagnosis is sometimes suspected by the patients themselves based on food withdrawal and 
introduction. Physicians may then concur if there has been the exclusion of other forms of  
gluten-induced disease (CD and WA) by appropriate serological and/or biopsy tests. Specific IgE 
might normalize if the patients are already on GFD and this might be a potential pitfall in diagnosis of 
WA The finding that symptoms disappear after gluten elimination adds weight to the diagnosis of 
NCGS, which is definitely proven by a double-blind (or open) oral gluten challenge performed after at 
least three weeks of GFD. 
Based on a combination of clinical, biological, genetic and histological data, it is possible to 
differentiate the three gluten-related conditions (WA, CD, and NCGS), using recently published 
algorithms [4]. Since there is some degree of overlap between NCGS and other forms of  
wheat-exclusion responsive conditions (e.g., IBS responsive to low FODMAPs diet, non-IgE mediated 
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WA), periodical patient reassessment (e.g., every 6–12 months), including an accurate dietary 
interview, is strongly recommended. 
10. Pathogenesis 
The pathophysiology of NCGS is under scrutiny. In the study conducted by Sapone et al. [2], 
NCGS subjects showed a normal intestinal permeability and claudin-1 and ZO-1 expression compared 
with celiac patients, and a significantly higher expression of claudin-4. In the same NCGS patients, the  
up-regulation of claudin-4 was associated with an increased expression of toll-like receptor-2 and a 
significant reduction of T-regulatory cell marker FoxP3 relative to controls and CD patients. 
Additionally, an increase in IELs of the classes α and β, but no increase in adaptive immunity-related 
gut mucosal gene expression, including interleukin (IL)-6, IL-21, and interferon-γ (IFN-γ), was 
detected in NCGS. These changes suggested an important role of the intestinal innate immune system 
in NCGS, without any involvement of the adaptive immune response. In a study aimed at exploring 
and comparing the early mucosal immunological events in CD and NCGS, Brottveit et al. confirmed 
that CD patients mounted a concomitant innate and adaptive immune response to gluten challenge. 
NCGS patients only showed increased IFN-γ levels after gluten challenge and increased density of 
intraepithelial CD3(+) T cells at baseline [38]. These findings open the possibility of an adaptive 
component as well in the pathogenesis of NCGS. 
The trigger/s of mucosal events leading to NCGS is not necessarily represented by the same array 
of gluten peptides responsible for CD development. Unlike the duodenal mucosa from patients with 
CD, upon incubation with gliadin, mucosa from patients with NCGS does not express markers of 
inflammation, and their basophils are not activated by gliadin [39]. In vitro studies suggest that wheat 
ATIs could play a major role as triggers of the innate immune response in intestinal monocytes, 
macrophages and dendritic cells eventually leading to NCGS. Wheat ATIs are a family of five or more 
homologous low-molecular-weight proteins highly resistant to intestinal proteolysis. They are known 
to be the major allergen responsible for baker’s asthma. ATIs engage the TLR4-MD2-CD14 complex 
and lead to up-regulation of maturation markers and elicit release of pro-inflammatory cytokines in 
cells from celiac and non-celiac patients and in celiac patients’ biopsies [40]. 
11. Current and Future Trends 
The vast majority of celiac experts initially reacted with a great deal of skepticism to the concept of 
NCGS existence and the fact that it was a separate entity from CD. For those that witnessed the initial 
struggle of convincing health care professionals that CD was not confined within European boundaries 
this was a déjà vu. Indeed, we are now with NCGS where we probably were with CD forty years ago. 
In the 1980s we knew that CD existed, but we had little information on the mechanisms leading to the 
enteropathy, the genetic component of the disease, what kind of immune response was involved in the 
pathogenesis of the disease, its multifaceted clinical presentation, and its complication. We lacked 
robust screening tools to conduct well-design epidemiological studies and had little understanding on 
the most appropriate management of the disease and its complications. The confusion about NCGS 
stems from the few facts, and the many fantasies, currently available on this topic. The best testimonial 
of this concept is the comparison of the literature published on both conditions during the past  
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63 years. The publications on CD doubled every 20 years from approximately 2500 in the period of 
1950–70 to ~9500 in the period 1991–2010, with already more than 2000 papers published between 
2011 and 2013. Conversely, there were almost no scientific reports on NCGS before 1970 and only a 
handful number of papers have been published ever since, most of them after 2005. The increase 
interest in NCGS is testified by the decreased NCGS/CD publication ratio that dropped from 1:438 in 
the period 1950–70 to 1:10 in the period 2010–13 (Table 1). 
Table 1. Trends in publication on celiac disease (CD) and non-celiac gluten sensitivity 
(NCGS) during the last decades. 
Timeline CD NCGS NCGS/CD ratio 
1950–1970 2632 6 1:438 
1971–1990 4915 118 1:43 
1991–2010 9498 733 1:13 
2011–2013 2014 188 1:10 
Given the limited literature on the topic, it should not come as a surprise that there are still 
numerous questions about NCGS that should be addressed. Is NCGS permanent or transitory? Is the 
threshold of sensitivity the same for everybody, or change from subject to subject and in the same 
subject over time? How frequent is NCGS? The range reported in the literature is between 0.5% and 
6%, based on poorly conducted studies and on definitions of the disease that varies widely from one 
report to another. Only recently, well-conducted studies based on double blind, placebo control design 
are providing evidence-based data on the prevalence of NCGS in specific clinical conditions, 
particularly IBS [13]. There is the strong need for more coordinated efforts to perform large 
multicenter studies for those conditions, including autism and schizophrenia, in which NCGS has been 
indicated as a possible cause in a subgroup of these patients. The lack of validated biomarkers for a 
diagnosis not based on exclusion criteria is judged to be of paramount importance by many experts in 
the field. Currently a large multicenter placebo-controlled study is underway to achieve this goal and, 
hopefully, will provide tools for a more correct diagnosis and for more rigorous studies to establish the 
prevalence of NCGS in specific conditions and in the general population. Recent studies raised the 
possibility that, beside gluten [13] and wheat ATIs [40], low-fermentable, poorly-absorbed,  
short-chain carbohydrates [21] can contribute to symptoms (at least those related to IBS) experienced 
by NCGS patients. These new findings need corroboration through additional studies involving larger 
numbers of subjects. If these studies will confirm these new findings, they will probably prompt a 
change in nomenclature from NCGS to wheat sensitivity to reflect the fact that, beside gluten, other 
components of wheat may be responsible for the symptoms reported by NCGS patients. 
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